Committee Seeks More Information On Long-Term Use Of Xifaxan For IBS-D
This article was originally published in The Pink Sheet Daily
Executive Summary
Success in a single course of treatment is not enough to identify patients for long-term intermittent treatment with the antibiotic, the Gastrointestinal Drugs Advisory Committee tells FDA Nov. 16
You may also be interested in...
Panel To Help Define Target Population For Xifaxan Reuse In IBS-D
FDA’s Gastrointestinal Drugs Advisory Committee Nov. 16 will review a trial design for evaluating the safety and efficacy of retreatment for the chronic condition with Silax’s antibiotic Xifaxan.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.